RenovoRx, Inc. has secured a Notice of Allowance for its first Japanese patent application, enhancing the intellectual property protection for its RenovoCath device. This novel dual-occlusion catheter-based system is designed for targeted drug delivery through the vasa vasorum, the small blood vessels that supply nutrients to artery walls. The patent covers a method that enables precise localization and controlled infusion of therapeutics directly to tumor sites, which could significantly improve treatment outcomes while minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy.

The significance of this patent lies in its potential to revolutionize targeted drug delivery in oncology. By utilizing the vasa vasorum as a pathway for therapeutic agents, RenovoCath aims to overcome the limitations of both systemic and local therapies. This method could lead to enhanced efficacy and reduced toxicity, addressing a critical need in cancer treatment where conventional methods often result in debilitating side effects. The patent also strengthens RenovoRx’s position in the Japanese market, a strategic area for expanding its commercial reach and partnerships.

This development underscores a shift in the oncology landscape towards more localized therapies that prioritize patient safety and treatment effectiveness. As RenovoRx actively commercializes RenovoCath in the U.S. and explores opportunities in Japan, this patent could accelerate timelines for drug development and regulatory approvals. The ongoing Phase III TIGeR-PaC trial, evaluating the intra-arterial delivery of gemcitabine via RenovoCath, exemplifies the potential for innovative drug-device combinations to transform treatment paradigms in oncology, potentially leading to improved clinical outcomes for patients with challenging malignancies.

Source: globenewswire.com